Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Britain's NHS Test and Trace reducing size of contact tracing workforce

Published 30/04/2021, 23:56
Updated 01/05/2021, 00:00
© Reuters. FILE PHOTO: A government and NHS Test and Trace advert is seen on a billboard in London

By Kanishka Singh

(Reuters) - Britain's NHS (National Health Service) Test and Trace system is reducing the size of its contact tracing workforce after a decline in coronavirus cases in the country.

"Just as we increased numbers working in the trace service over the winter, we are now responding to the reduction in case numbers we've seen this spring", a spokeswoman for the Department for Health and Social Care said in an emailed statement on Friday.

"We are continuing to respond to changes in demand and reflect staff numbers accordingly", the statement added.

The statement did not specify by how much the staff is being reduced. It said that NHS Test and Trace has contacted almost 10 million people since it began.

A total of more than 34.2 million people in Britain have been given a first dose of COVID-19 vaccine, government statistics showed on Friday. A further 2,381 people had tested positive for the virus, down slightly on the day before.

There were 15 new deaths recorded within 28 days of a positive test, compared to the 22 deaths recorded on Thursday.

Earlier in April, Britain's health ministry said there were no plans to halt rapid coronavirus testing.

Britain will buy 60 million more doses of Pfizer/BioNTech's, vaccine, health minister Matt Hancock said earlier this week, in a deal that more than doubles the country's supply of the shot ahead of a booster programme later this year.

Britain has now ordered a total of 100 million doses of the Pfizer (NYSE:PFE) vaccine, one of three COVID-19 shots being rolled out in the country.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Britain, which has a population of 67 million, has deals for 517 million doses of eight different COVID-19 vaccines, some of which remain under development.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.